Retrotope (@Retrotope1) header
Retrotope (@Retrotope1) profile picture
Joined December 2017
Photo by Retrotope (@Retrotope1)Photo by Retrotope (@Retrotope1)Photo by Retrotope (@Retrotope1)
Happy to share 1st data for RT011, 2nd program from our proprietary drug dev platform. Preclinical results being presented from models of retinal degeneration. IND planned for dry AMD in 1H '22. See our press release for more details on the presentations. retrotope.com/press-release/…
2
This morning we reported data from Phase 2/3 study of RT001 in INAD, an ultra-rare, progressive and fatal infant genetic disease. Read our press release highlighting the results, and our plans to discuss the data and next steps with FDA. #rarediseases retrotope.com/press-release/…
2
Proud to announce the initiation of new P2 trial of RT001. First patient has been dosed in progressive supranuclear palsy (#PSP) study and enrollment is proceeding rapidly. Joins ongoing RT001 trials in #ALS and Friedreih’s ataxia. #rarediseases retrotope.com/press-release/…
Sarah Endemann, our manager, clinical ops & patient relations, will speak at 11th International NBIA Disorders Association Family Conference. Her talk will highlight Retrotope’s RT001 program in #INAD and work on an INAD assessment scale. #rarediseases nbiadisorders.org/2021-agend…
2
Despite pandemic, Retrotope beat P2 #ALS study target enrollment in under six weeks. Shows desperate need for new treatments & excitement for RT001’s unique mechanism. #LouGehrig #RareDiseases retrotope.com/completion-of-…
1
Today marks a key milestone in our efforts to develop a new treatment for patients with #ALS. First several patients have been dosed in our P2 study of RT001 and enrollment is proceeding rapidly. Data expected by year's end. #LouGehrig #rarediseases retrotope.com/initiation-of-…
Friedreich’s Ataxia News helped spread the word about our recent rare pediatric disease and Fast Track designations for RT001 in FA. Our pivotal P2/3 trial in FA is fully enrolled with data expected by the end of 2021. #friedreichsataxia #rarediseases friedreichsataxianews.com/ne…
Retrotope's rare pediatric disease designation for RT001 in INAD was included in AAO's "Week in Review" of ophthalmic news. Did you know Retrotope also has a preclinical program in dry AMD? An IND filing for RT011 is expected in 2021. #INAD #dryAMD aao.org/headline/week-in-rev…
See our presentation at the recent 2021 BIO CEO & Investor Digital Conference to get the latest update on Retrotope's clinical-stage drug development efforts for various #neurodegenerative diseases. youtu.be/gBzXp7WnRl8 #INAD #Friedreichsataxia #ALS #rarediseases #dryAMD
1
Our president and CBO, Anil Kumar, will discuss the latest on Retrotope’s drug development efforts for a range of #neurodegenerative diseases as part of #HCWCO’s Global Life Sciences Conference. retrotope.com #INAD #Friedreichsataxia #ALS #rarediseases
1
FDA grants Retrotope’s RT001 rare pediatric disease designation in two life-threatening neurodegenerative indications. Data readouts from trials in both indications expected by end of ’21. retrotope.com
1
1
Retrotope is pleased to welcome Rick E Winningham, CEO of $TBPH, as our new chairman. His drug development, regulatory and commercial expertise will serve us well with several key clinical trial data readouts expected in 2021. retrotope.com/retrotope-appo…
1
1
1
Today is #rarediseaseday. Please #showyourstripes and help encourage the development of drugs for so many untreatable rare, orphan diseases.